Boehringer Boosts Pipeline, Adding Oral Small Molecules With Broad Immunology & Inflammation Potential
Boehringer Ingelheim receives rights to oral small molecules from Sitryx with potential applications in multiple autoimmune disorders. Depending on the progress of Boehringer’s research, Sitryx could receive more than $500 million.